Rating Change
Cantor Fitzgerald analysts initiated coverage on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) with a rating of Overweight on October 15, 2026.
new coverageNASDAQ:ARQT
Cantor Fitzgerald Initiates Coverage on Arcutis Biotherapeutics, Inc. (ARQT) with Overweight
Cantor Fitzgerald analysts initiated coverage on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) with a rating of Overweight on October 15, 2026.
At publication ·
What changed
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) · new coverage
- Firm
- Cantor Fitzgerald
- Rating
- Overweight
- Price at event
- $28.42
- Market capitalization
- $3.3B
At a glance
Key takeaways
- Cantor Fitzgerald initiated Overweight coverage on Arcutis Biotherapeutics (ARQT) on October 15, 2026, as the stock trades at $28.42 with a $3.3B market capitalization.
Market Context
Arcutis Biotherapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $28.42 with a market capitalization of $3.3B.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Arcutis Biotherapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Arcutis Biotherapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 15, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Aug 06, 2026 | Morgan Stanley | Overweight | N/A |
| Aug 06, 2026 | Guggenheim | Buy | N/A |
| Aug 06, 2026 | Needham | Buy | N/A |
| May 07, 2026 | Needham | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ARQT Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ARQT?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ARQT forecast page.